Novartis Investigative Site
Houma, Louisiana 70360
0 studies enrolling now · 4 studies all time
What they study most
Atherosclerosis, Cardiovascular Disease and Lipoprotein(a), Heart Failure With Preserved Ejection Fraction
Studies at this site
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
- Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
- A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
- Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed